34results about How to "Delay slowing" patented technology

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.

The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).

The present invention provides novel clustered multi-antigenic constructs having the structure:

The present invention relates to methods for treating a disease, in which the disease arises from dysregulation of the Wnt signaling pathway. In some instances, the disease can be treated by administering a Wnt pathway inhibitory compound. In other instances, the method optionally includes conducting a genome-wide screening to determine one or more genes resulting in a reduced disease state and then identifying the gene(s) as being involved in the Wnt signaling pathway.

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiomyopathies. The inventors showed that the nicotinamide riboside kinase Nmrk2 gene involved in NAD+ biosynthetic pathway is strongly induced in the heart of the mouse models of dilated cardiomyopathy and that Nmrk2 is an AMPK and PPARα responsive gene. They also showed that the NMRK enzymes substrate nicotinamide riboside supplementation in food markedly improves cardiac functions and reduces eccentric remodeling. The inventors demonstrated that both the NMRK1 and NMRK2 protein are expressed in the human healthy heart, that NMRK2 protein level is increased in human failing hearts as it is the case in mouse failing hearts in several models of heart failure and cardiomyopathies. In particular, the present invention relates to nicotinamide riboside for use in the treatment of cardiomyopathy in a human subject in need thereof.

The present invention relates to a metal-organic framework composition, as well as constructs and methods thereof. In one particular example, the composition provides a platform having an emission signal in the deep red to near-infrared (NIR) region.

The disclosure provides polynucleotides containing outer hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in outer hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote outer hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss.

The present disclosure relates to methods and pharmaceutical compositions for the treatment of hepatocellular carcinomas (HCC in abbreviation, the term “hepatocellular carcinoma” has its general meaning in the art and refers to the cancer developed in hepatocytes see page 2 lines 24-30 of the present application) comprising administering to the subject a therapeutically effective amount of an inhibitor of NTSR1 (Neurotensin Receptor 1) activation or expression. The examples show the expression of NTSR1 in HCC cell lines and the role of the NTS/NTSR1 complex in these cell lines, thereby showing the role of the complex in tumour progression.

The disclosure provides polynucleotides containing inner hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in inner hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote inner hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss.

The present invention relates to a construct including a porous core, a cargo, and a spacer disposed between the core and the cargo. In some examples, the construct further includes an outer layer composed of a lipid, a polymer, or a combination thereof. Methods of making and employing such constructs are also described herein.

The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or/and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.